AKESO(HK:09926) Jin Rong Jie·2025-12-12 04:02Core Viewpoint - Kangfang Biopharma (09926) has seen a stock increase of over 3%, currently at 121.9 HKD, with a trading volume of 271 million HKD, following the announcement of FDA approval for its innovative PD-1/CTLA-4 bispecific antibody, Cadonilimab, for a Phase III clinical trial [1] Group 1 - The FDA has approved the international multicenter Phase III clinical study (COMPASSION-37/AK104-311) for Cadonilimab in combination with chemotherapy for HER2-negative, untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma [1] - COMPASSION-37 is the second international multicenter registration clinical study for Cadonilimab, following a previous study for immune-resistant hepatocellular carcinoma that has already commenced in the U.S. [1] - The initiation of the COMPASSION-37 study marks a significant step forward in the global development of Cadonilimab and is a key initiative in Kangfang Biopharma's globalization strategy, reinforcing its international leadership in the field of tumor immunotherapy 2.0 [1]